Vigil Neuroscience (NASDAQ:VIGL – Get Free Report) announced its earnings results on Thursday. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08), Zacks reports.
Vigil Neuroscience Stock Performance
NASDAQ:VIGL opened at $2.02 on Friday. Vigil Neuroscience has a 1 year low of $1.49 and a 1 year high of $6.06. The stock has a market cap of $82.58 million, a price-to-earnings ratio of -0.98 and a beta of 1.82. The business has a fifty day moving average of $2.34 and a 200-day moving average of $2.79.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on the company. Guggenheim reaffirmed a “buy” rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. William Blair started coverage on Vigil Neuroscience in a research report on Wednesday, December 4th. They set an “outperform” rating on the stock. HC Wainwright dropped their price target on Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday. JMP Securities reissued a “market outperform” rating and set a $22.00 price target on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Finally, Wedbush lowered their price objective on Vigil Neuroscience from $24.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vigil Neuroscience has an average rating of “Buy” and a consensus target price of $16.25.
About Vigil Neuroscience
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Further Reading
- Five stocks we like better than Vigil Neuroscience
- Most Volatile Stocks, What Investors Need to Know
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Consumer Staples Stocks, Explained
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Why Costco Stock Is Poised to Hit $1,000 Again Soon
Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
